$11.26
Today
as of Aug 5, 16:55 ET
Last 30 days
Recent Press Releases & News
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
Overview
52-week range
$11
$70
1% of range
Avg surprise (last 3)
-11.9%
Avg reaction (last 2)
+1.0%
100% positive
Latest IV / EM
94%
EM ±15.8% · $13 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-2.93 | $-2.38 | -23.1% | -3.2% | +0.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-3.59 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-3.86 | $-3.10 | -24.5% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-2.84 | $-3.23 | +12.1% | — | +1.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-22.68 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1920.85 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-535.72 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-38.63 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-49.23 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | BMO | -$2.71 | -$3.86 | +29.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7M | — | $3M | $2M | $2M | — | $3M | $2M |
| Cost of revenue | $2M | — | $1M | $3M | $943,000 | — | $2M | $3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-42M | — | $-33M | $-28M | $-16M | — | $-16M | $-77M |
| Net income | $-40M | — | $-32M | $-28M | $-17M | — | $-14M | $-79M |
| EPS (diluted) | $-2.93 | — | $-3.59 | $-3.86 | $-2.84 | — | $-22.68 | $-1920.85 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $185M | $208M | $190M | $125M | $132M | $99M | $28M | $4M |
| Inventory | — | — | — | — | — | — | $8M | $9M |
| Total current assets | $207M | $229M | $208M | $144M | $150M | $119M | $51M | $25M |
| Total assets | $258M | $277M | $252M | $187M | $193M | $163M | $95M | $70M |
| Long-term debt | — | — | — | — | — | $5M | $5M | $6M |
| Total liabilities | $31M | $32M | $21M | $19M | $12M | $23M | $21M | $28M |
| Total equity | $227M | $245M | $231M | $168M | $180M | $140M | $74M | $42M |